Merck Bolsters Oncology Pipeline with $2.13 Billion SciBrunch Licensing Deal for KRAS G12D Inhibitor

In a significant move to reshape its oncology portfolio ahead of impending patent cliffs, Merck & Co. has secured exclusive global rights to develop, manufacture, and commercialize SPR2015, a preclinical-stage oral precision cancer candidate. The deal, struck with the Shanghai-based biotech firm SciBrunch Therapeutics, represents a major validation for the Chinese drug developer and a tactical expansion for the American pharmaceutical giant. Under the terms of the agreement, SciBrunch stands to receive up to $2.13 billion, including an initial upfront payment of $400 million, with the remainder contingent upon achieving a series of rigorous development, regulatory, and commercial milestones.

The acquisition marks a strategic bet on SPR2015, a "molecular glue" designed to inhibit the KRAS G12D mutation—a notoriously difficult oncogenic target implicated in some of the most aggressive forms of cancer, including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and pancreatic ductal adenocarcinoma (PDAC).

The KRAS Challenge: Targeting the "Undruggable"

The KRAS G12D mutation is widely recognized as the most prevalent oncogenic RAS mutation in human solid tumors. According to a 2023 study published in the Journal of Clinical Oncology, this specific mutation appears in approximately 38% of cases across pancreatic, colorectal, and lung cancers. The mutation, caused by a simple substitution of glycine for aspartate at position 12, locks the KRAS protein into a constitutively active state, forcing the cell into a perpetual cycle of proliferation and survival signaling.

For years, the RAS pathway was considered "undruggable" due to the protein’s smooth surface and high affinity for GTP. However, the emergence of covalent and non-covalent inhibitors has transformed the landscape. SciBrunch’s candidate, SPR2015, functions as a highly selective molecular glue, a sophisticated class of drugs that bring the target protein into proximity with an E3 ubiquitin ligase, effectively tagging it for degradation. By specifically targeting the "ON" state of KRAS G12D, SPR2015 aims to shut down the signaling pathway while sparing wild-type KRAS cells, thereby minimizing the toxic side effects often associated with systemic chemotherapy.

Chronology of a Strategic Partnership

The path to this $2.13 billion agreement began in the laboratory, with SciBrunch’s intense focus on small-molecule oncology. Founded in 2014 by serial entrepreneur and CEO Tao Hu, PhD, alongside medicinal chemist Yang Zhang, PhD, the company has spent the last decade building a pipeline based on clinically validated targets.

The company’s progress accelerated significantly in early 2026. At the American Association for Cancer Research (AACR) Annual Meeting, SciBrunch researchers unveiled the first comprehensive preclinical data for SPR2015. The presentation, led by Dr. Hu, highlighted the compound’s potent antitumor efficacy in both cell-derived (CDX) and patient-derived (PDX) xenograft models.

By the summer of 2026, the potential of the molecule became clear to global investors and partners. Following a successful Pre-A funding round in January 2026—which raised over $35 million led by HighLight Capital—the company focused on IND-enabling studies. The subsequent acquisition by Merck, which involves an immediate $400 million pre-tax charge to Merck’s third-quarter earnings (roughly $0.13 per share), effectively fast-tracks the candidate into a more robust development environment. While the parties have not disclosed a specific timeline for Phase I human trials, the industry expectation remains that the compound is on a rapid path toward clinical evaluation.

Supporting Data: Evidence of Efficacy

The primary draw for Merck lies in the head-to-head performance data that SciBrunch generated during its preclinical phase. In a controlled mouse study comparing a single oral 100 mg/kg daily dose of SPR2015 against an unspecified competing G12D (ON) inhibitor, the SciBrunch candidate demonstrated superior performance.

Across a rigorous test set of 15 colorectal cancer CDX and PDX models, SPR2015 achieved a 64.7% objective response rate (ORR) and a 94.1% disease control rate (DCR) as a monotherapy. These results are particularly striking given the aggressive nature of the tumor types tested.

However, industry analysts maintain a degree of cautious optimism. Sreyashi Paul, a business analyst with Lucidquest Ventures, noted that while the preclinical data is compelling, the challenge lies in the "translational gap"—the ability of these potent properties to hold up in human physiology, especially given that other companies like Revolution Medicines and Verastem have already established a clinical head start in the G12D space.

For instance, Revolution Medicines’ zoldonrasib (RMC-9805) has already reported a 52% confirmed ORR in previously treated NSCLC patients. Similarly, Verastem’s VS-7375 has shown promising results in metastatic PDAC, with 93% of patients in a Phase I/II trial showing significant reduction in tumor markers. Merck’s acquisition of SPR2015 suggests that they believe the compound’s unique molecular glue mechanism offers a "best-in-class" profile that could surpass these early benchmarks once it enters the clinic.

Official Responses and R&D Strategy

The leadership on both sides of the deal emphasized the long-term scientific value of the collaboration.

"This agreement with Merck not only validates the R&D strength of our platform but also underscores the potential of SPR2015 in addressing longstanding unmet medical needs in oncology," said Tao Hu, SciBrunch’s CEO. "We are excited that Merck, a global leader in oncology, will take SPR2015 forward."

George Addona, senior vice president of discovery, preclinical development, and translational medicine at Merck Research Laboratories, echoed this sentiment. "Evidence continues to accumulate for the therapeutic potential of targeting the KRAS pathway, a well-characterized factor in tumor cell growth. This agreement complements and diversifies our expanding pipeline of precision targeted candidates with SPR2015, a potent engineered inhibitor for one of the most prevalent mutant forms of KRAS found in human cancers."

The deal represents a broader trend of Western pharmaceutical firms looking to China’s burgeoning biotech sector to revitalize their late-stage pipelines. For Merck, this is a matter of institutional survival and growth.

Implications: The Post-Keytruda Era

The acquisition must be viewed through the lens of Merck’s "Keytruda problem." Keytruda (pembrolizumab), the company’s blockbuster immunotherapy, is a global sales juggernaut, generating $31.641 billion in 2025 and over $15 billion in the first half of 2026 alone. However, with patent exclusivity for Keytruda in the U.S. expected to expire in 2028, Merck is under immense pressure to find the next generation of blockbuster drugs.

Wall Street analysts currently forecast peak annual revenue for Keytruda to hit $33 billion by 2028. To bridge the potential revenue gap that will follow the arrival of biosimilars, Merck has set an ambitious target of creating over $70 billion in commercial opportunity by the mid-2030s.

Investing in SPR2015 is a foundational step in this strategy. By building a diverse "cocktail" of precision oncology candidates, Merck aims to move beyond its reliance on a single asset. SciBrunch, meanwhile, has signaled that it intends to continue its research mission. While SPR2015 was a crown jewel of its portfolio, the company is concurrently advancing SPR1020, a brain-penetrant PARP1 selective inhibitor currently in Phase I/II trials (NCT07359066) for patients with advanced solid tumors, including glioblastoma and metastatic brain cancer.

Conclusion: A New Chapter for Precision Medicine

The collaboration between Merck and SciBrunch is more than a simple financial transaction; it is a high-stakes alignment of capital and innovation. By handing over the development of SPR2015 to Merck, SciBrunch has ensured that its most promising molecule will receive the massive resource allocation required to navigate the complexities of global clinical trials and regulatory scrutiny.

For Merck, the deal is a testament to the fact that the next wave of cancer innovation is increasingly global and distributed. As the company prepares for the post-Keytruda era, the success of SPR2015 could define its ability to maintain its dominance in the oncology space. Whether the compound can clear the hurdle of human clinical trials and repeat the success seen in its preclinical models remains the pivotal question for the next three to five years of pharmaceutical development. For patients suffering from KRAS-mutated cancers, the deal offers a glimmer of hope that a targeted, effective, and oral treatment may soon be within reach.